Rachel Roubein is a reporter at The Washington Post. She focuses on health and wellness, particularly in relation to the Food and Drug Administration, covering topics such as pharmaceutical regulation, public health, and healthcare administration. Rachel's work has been featured in numerous publications, including POLITICO, The Boston Globe, and Yahoo News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Rachel Roubein
But Food and Drug Administration scientists and some medical experts have raised alarms about increasing access to certain peptides. That's because many of the products' claims haven't gone through the rigorous clinicals trials that FDA-approved drugs undergo to assess safety and efficacy.
By: Rachel Roubein
The US administration’s move comes as Food and Drug Administration scientists and some medical experts raise concerns about increasing access to certain peptides.
By: Daniel Wu, Rachel Roubein
The state is experiencing the nation’s worst ongoing measles outbreak, the first in the U.S. to top more than 1,000 cases since 1991.
By: Rachel Roubein
The unusual enforcement mechanism for Texas' abortion ban is on trial.
By: Rachel Roubein
Means has been a key player in Kennedy’s Make America Healthy Again movement.
By: Caitlin Gilbert, Rachel Roubein
Americans are eating more imported fruits and vegetables, but less than 10 percent of facilities that account for 90 percent of shipments have been inspected since 2009.
By: Rachel Roubein, Caitlin Gilbert
But the FDA rarely inspects those manufacturers that ship produce to the U.S.
By: Rachel Roubein, Daniel Wu
Health Secretary Robert F. Kennedy Jr. pins blame on Muslim Brotherhood while campaigning for GOP candidates in Michigan in remarks that drew strong backlash.
By: Rachel Roubein, Daniel Wu
The Washington Post Oct. 27, 2026, 4:33 p.m. ET Health Secretary Robert F.
By: Rachel Roubein
The Trump administration published a draft policy for widening access to controversial peptides while federal officials continue to hammer out permanent rules for the products.
